New hope for kidney transplant patients: delaying stronger drugs may speed recovery
NCT ID NCT06091995
First seen Apr 05, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study tested whether giving one dose of belatacept can safely delay the start of a stronger anti-rejection drug (tacrolimus) in kidney transplant patients whose new kidneys are slow to start working. 67 adults with delayed graft function took part. Researchers tracked how quickly kidneys recovered, and monitored for rejection, infections, and survival over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for USE OF BELATACEPT IN KIDNEY TRANSPLANT PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Methodist Dallas Medical Center
Dallas, Texas, 75203, United States
Conditions
Explore the condition pages connected to this study.